[Progress on study of treatment of age-related macular degeneration by pigment epithelial-derived factor].
Age-related macular degeneration (AMD) is a common cause of blindness in elderly population. Exploration of effective treatment of AMD has important significance. Pigment epithelial-derived factor (PEDF) is the most powerful endogenous inhibitor of angiogenesis. Increasing evidences, including results of phase I clinical trial, indicated that PEDF could significantly inhibit the development of choroidal neovascularization, which is the characteristic of wet AMD. Therefore, PEDF is one of the most potential therapeutic agents for AMD treatment.
Hou
Hui-yuan
HY
Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Wang
Yu-sheng
YS
D020256:Choroidal Neovascularization; D005136:Eye Proteins / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D015843:Serpins / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor